BUSINESS WIRE--Medtronic, Inc. (NYSE: MDT - News) today announced U.S. Food and Drug Administration (FDA) approval and availability of the Attain Ability® left-heart lead (Model 4196) for use with cardiac resynchronization therapy (CRT) devices for heart failure patients. Attain Ability has the thinnest lead body of any left-heart lead currently available, providing physicians with a tool to deliver therapy directly to hard-to-reach areas of the heart. Attain Ability incorporates insulation material developed by NASA Langley Research Center that was previously evaluated for space applications, high-performance engines and harsh environments. This application marks the first time a NASA-developed material has been used in this kind of implantable medical device.
